Physician profile
Jennifer E Payne
NPI 1144304841
$3,676.83
in general payments reported to CMS, 2019-2025
50 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $2,130 · 2023: $550 · 2024: $576 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.36 |
| Education | $224.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $442.53 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $269.71 | 2021-2024 | Ultomiris |
| Astellas Pharma US INC | $198.99 | 2024 | |
| Genentech USA, INC. | $191.84 | 2022-2023 | Polivy, Lunsumio, Venclexta |
| Abbvie INC. | $190.90 | 2022-2025 | |
| Ucb, INC. | $175.32 | 2021-2024 | Briviact, Zilbrysq, Nayzilam |
| Merck Sharp & Dohme LLC | $163.98 | 2022-2025 | Keytruda, Lynparza |
| Jazz Pharmaceuticals INC. | $139.17 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $138.04 | 2022-2025 | Enhertu, Imfinzi |
| Aveo Pharmaceuticals, INC. | $137.78 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $130.77 | 2022-2025 | Opdualag, Opdivo |
| Incyte Corporation | $117.27 | 2022-2023 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $101.65 | 2022-2023 | |
| Janssen Biotech, INC. | $92.34 | 2022-2024 | Rybrevant, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $84.87 | 2022-2025 | Enhertu |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.